NeuWave Medical is engaged in the production and marketing of minimally invasive soft tissue microwave ablation systems.

The acquisition is part of Johnson & Johnson Medical Devices’ strategy to invest in the areas of unmet medical needs like surgical oncology.

NeuWave’s Certus 140 ablation system features high-powered computer and touchscreen interface, which allows activation of single or simultaneous multiple probe procedures for patients with soft tissue lesions.

It helps physicians in the treatment of ablations for lesions of varying shapes and sizes.

NeuWave Medical’s probe family also features conventional probes and thePrecision PR probe to limit the ablation length, resulting in precise and controlled ablations.

Ethicon Group company chairman Michael del Prado said: "We continue to work to push the boundaries of access and treatment for patients for whom traditional surgery may not be an option today.

"The market-leading technology and expertise that NeuWave Medical has developed is minimally invasive and can be combined with other therapies to improve outcomes for patients."

Subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, the deal is expected to complete in the second quarter of this year.

Ethicon produces surgical products such as sutures, staplers, energy devices, trocars and hemostats, which will be used to treat severe medical conditions like obesity and cancer.

Image: Ethicon to acquire medical device firm NeuWave Medical. Photo: courtesy of stockimages /